BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 1, 2023
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Bristol Myers Squibb acquires Orum’s GSPT1 degrader ORM-6151 for AML and MDS
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Bristol Myers Squibb acquires Orum’s GSPT1 degrader ORM-6151 for AML and MDS
Nov. 7, 2023
No Comments
Orum Therapeutics Inc. has entered into a definitive agreement under which Bristol Myers Squibb Co. has acquired Orum’s ORM-6151 program.
BioWorld Science
Cancer
Immuno-oncology
